OTCMKTS:RLMD - Relmada Therapeutics Stock Price, Forecast & News

Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RLMD shares have decreased by 15.8% and is now trading at $33.83. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Relmada Therapeutics.

Relmada Therapeutics Inc (OTCMKTS:RLMD) posted its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. View Relmada Therapeutics' earnings history.

2 equities research analysts have issued 12-month price objectives for Relmada Therapeutics' stock. Their forecasts range from $64.00 to $75.00. On average, they anticipate Relmada Therapeutics' stock price to reach $69.50 in the next twelve months. This suggests a possible upside of 105.4% from the stock's current price. View analysts' price targets for Relmada Therapeutics.

Media stories about RLMD stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Relmada Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutRelmada Therapeutics.

Based on aggregate information from My MarketBeat watchlists, some companies that other Relmada Therapeutics investors own include Allena Pharmaceuticals (ALNA), Primo Water (PRMW), Tesla (TSLA), Energy Transfer LP Unit (ET), Actinium Pharmaceuticals (ATNM), NovaBay Pharmaceuticals (NBY), Abeona Therapeutics (ABEO), Amarin (AMRN), Huntington Bancshares (HBAN) and Marinus Pharmaceuticals (MRNS).

Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD."

Relmada Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (8.86%), RA Capital Management L.P. (5.19%), Parsons Capital Management Inc. RI (2.68%), Boxer Capital LLC (2.04%), Tiedemann Advisors LLC (1.93%) and Franklin Resources Inc. (1.53%). View institutional ownership trends for Relmada Therapeutics.

RLMD stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, RA Capital Management L.P., Parsons Capital Management Inc. RI, Boxer Capital LLC, Tiedemann Advisors LLC, Franklin Resources Inc., Broadfin Capital LLC, and Point72 Asset Management L.P.. View insider buying and selling activity for Relmada Therapeutics.

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RLMD stock can currently be purchased for approximately $33.83.

Relmada Therapeutics has a market capitalization of $496.42 million. Relmada Therapeutics employs 3 workers across the globe. View additional information about Relmada Therapeutics.